A plant-derived recombinant human glucocerebrosidase enzyme - A preclinical and phase I investigation

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Aviezer, David ^a   Brill Almon, Einat ^a   Shaaltiel, Yoseph ^a   Hashmueli, Sharon ^a   Bartfeld, Daniel ^a   Mizrachi, Sarah ^b   Liberman, Yael ^b   Freeman, Arnold ^b   Zimran, Ari ^c   Galun, Eithan ^b  

^a Protalix Biotherapeutics   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMIGLUCERASE; PLACEBO; RECOMBINANT ENZYME; RECOMBINANT GLUCOSYLCERAMIDASE; UNCLASSIFIED DRUG; GLUCOSYLCERAMIDASE; HYBRID PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; LABORATORY TEST; MALE; MAMMAL CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLANT CELL; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICOKINETICS; TREATMENT DURATION; VITAL SIGN; ANIMAL; ANTIBODY PRODUCTION; CARROT; CELL CULTURE; CYTOLOGY; DRUG SCREENING; ECONOMICS; ENZYMOLOGY; GAUCHER DISEASE; GENETIC TRANSFECTION; GENETICS; HALF LIFE TIME; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MACACA; SERODIAGNOSIS;

ANIMALIA; MAMMALIA; PRIMATES;

ADULT; ANIMALS; ANTIBODY FORMATION; CELLS, CULTURED; CLINICAL TRIALS, PHASE III AS TOPIC; DAUCUS CAROTA; DRUG EVALUATION, PRECLINICAL; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; YOUNG ADULT;

EID: 62849111312     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004792     Document Type: Article

References (22)

1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, et al. (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470.
2. Beutler E (2004) Enzyme replacement in Gaucher disease. PLoS Med 1: e21. Epub 2004 Nov 2030.
3. Beutler E (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88: 208-215.
4. Zimran A, Bembi B, Pastores G (2006) Enzyme replacement therapy. In: Futerman AH, Zimran A, eds. Gaucher Disease. Boca Raton, FL: CRC Press, Taylor and Francis Group. Chapter 22.
5. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, et al. (2001) A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722.
6. Brady RO (2006) Enzyme Replacement for Lysosomal Diseases. Annual Review of Medicine 57: 283-296.
7. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, et al. (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749.
8. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113: e448-457.
9. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, et al. (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144: 574-580.
10. Wraith EJ, Hopwood JJ, Fuller M, Meikle PJ, Brooks DA (2005) Laronidase treatment of mucopolysaccharidosis I. BioDrugs 19: 1-7.
11. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, et al. (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167: 267-277.
12. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25: 147-151.
13. Pollack A (2008) Cutting Dosage of Costly Drug Spurs a Debate. New York Times.
14. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, et al. (2007) Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J Sep;5: 579-590.
15. Kaiser J (2008) Is the drought over for pharming? Science Apr 25;320(5875): 473-475.
16. Weinreb N (2008) Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opinion on Pharmacotherapy 9: 1987-2000.
17. Starzyk K, Richards S, Yee J, Smith SE, Kingma W (2007) The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab Feb 90: 122-125.
18. Ponce E, Moskovitz J, Grabowski G (1997) Enzyme Therapy in Gaucher Disease Type 1: Effect of Neutralizing Antibodies to Acid beta-Glucosidase. Blood 90: 43-48.
19. Zhao H, Bailey LA, Grabowski GA (2003) Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 30: 90-96.
20. Sijmons PC, Dekker BM, Schrammeijer B, Verwoerd TC, van den Elzen PJ, et al. (1990) Production of correctly processed human serum albumin in transgenic plants. Biotechnology (N Y) 8: 217-221.
21. Hellwig S, Drossard J, Twyman RM, Fischer R (2004) Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22: 1415-1422.
22. Arntzen C (2008) Plant science. Using tobacco to treat cancer. Science 321: 1052-1053.